Prelude Therapeutics partners with Eli Lilly on Phase 1 breast‑cancer trial
Prelude Therapeutics and Eli Lilly have entered a joint clinical‑trial and supply arrangement to test Prelude’s oral KAT6A degrader PRT13722 together with Lilly’s CDK4/6 inhibitor abemaciclib (Verzenio) and estrogen‑receptor antagonist imlunestrant (Inluriyo). The U.S. FDA cleared Prelude’s IND, allowing patient enrollment to start in the fourth quarter of 2026. The collaboration will evaluate PRT13722 as monotherapy and in combination cohorts for HR+/HER2‑negative breast cancer.
Why it matters
The deal gives Prelude access to Lilly’s established breast‑cancer drugs, potentially accelerating data generation for its lead candidate. Investors will watch the Phase 1 results expected in 2027, which could affect Prelude’s valuation and cash‑runway outlook.
Key facts
- 1Prelude and Lilly signed a clinical‑trial and supply agreement for PRT13722, abemaciclib and imlunestrant. stocktitan.net
- 2The FDA cleared Prelude’s IND application for PRT13722, permitting the Phase 1 study to proceed. stocktitan.net
- 3Patient enrollment is planned to begin in Q4 2026, starting with monotherapy dose escalation before expanding to combination cohorts. stocktitan.net
- 4The trial will target patients with HR+/HER2‑negative breast cancer. rttnews.com
- 5Prelude’s stock closed at $3.74 on Monday, up 6.42% in pre‑market trading after the announcement. rttnews.com
- 6Citizens reiterated a Market Outperform rating with a $6.00 price target following the collaboration. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.